articaine hydrochloride - Profile

What are the generic sources for articaine hydrochloride and what is the scope of freedom to operate?

Articaine hydrochloride is the generic ingredient in six branded drugs marketed by Thea Pharma, Hospira, Pierrel, Deproco, and Hansamed Inc, and is included in six NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Articaine hydrochloride has fifteen patent family members in eleven countries.

Summary for articaine hydrochloride

International Patents:	15
US Patents:	3
Tradenames:	6
Applicants:	5
NDAs:	6

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for articaine hydrochloride

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for articaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No	12,403,126		Y
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No	11,826,347		Y
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No	11,096,922		Y
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No
Hospira	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	079138-001	Jun 18, 2010		DISCN	No	No
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-001	Feb 26, 2010		RX	Yes	No
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-002	Feb 26, 2010		RX	Yes	Yes

International Patents for articaine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Australia	2020245203	Anesthetic composition and method of anesthetizing the eye
Australia	2025252666	Anesthetic composition and method of anesthetizing the eye
Brazil	112021019039	Composição anestésica e método de anestesia do olho
Canada	3134531	COMPOSITION ANESTHESIQUE ET PROCEDE D'ANESTHESIE DE L'OEIL (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
China	114072139	麻醉组合物和麻醉眼睛的方法 (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
European Patent Office	3946311	COMPOSITION ANESTHÉSIQUE ET PROCÉDÉ D'ANESTHÉSIE DE L'IL (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
Israel	286624	תכשיר אלחוש ושיטת אלחוש העין (Anesthetic composition and method of anesthetizing the eye)

Summary
This report assesses the investment landscape, market dynamics, and financial trajectory of articaine hydrochloride, a locally acting amide-type anesthetic widely used in dental procedures. Analysis includes current market size, growth drivers, competitive environment, regulatory considerations, and financial forecasts. The analysis aims to enable stakeholders to understand potential opportunities and risks associated with investing in or developing formulations of articaine hydrochloride.

---

Overview of Articaine Hydrochloride

Aspect	Details
Chemical Name	Articaine hydrochloride
Pharmaceutical Class	Amide local anesthetic
Mechanism of Action	Blocks nerve impulse conduction by sodium channel inhibition
Typical Uses	Local anesthesia in dental, maxillofacial, and minor surgical procedures
Approval Status	FDA-approved in the US, EMA-approved in EU

Market Size and Growth Overview

Last updated: February 3, 2026

Year	Global Market Size (USD million)	CAGR (2018–2023)
2018	280	—
2019	312	11.4%
2020	345	10.5%
2021	385	11.9%
2022	430	11.7%
2023	480 (projected)	—

Source: Industry reports, Grand View Research, 2023 [1]

The increasing demand for dental and outpatient surgical procedures globally, particularly in emerging markets, has driven steady growth in articaine hydrochloride sales. The market is projected to expand at a CAGR of approximately 11.4% through 2028, with Asia-Pacific displaying the fastest growth due to rising dental care awareness and expanding healthcare infrastructure.

---

Key Market Drivers

1. Rise in Dental Procedures: The global increase in dental cosmetic procedures and oral surgeries fuels demand for local anesthetics like articaine hydrochloride.
2. Superior Pharmacological Profile: Articaine’s rapid onset and high potency compared to lidocaine has shifted preferences among clinicians.
3. Regulatory Approvals & Branding: Several formulations and enhanced delivery systems have received regulatory approval, boosting market reach.
4. Emerging Markets Expansion: Low-cost oral health initiatives increase access, expanding market penetration.

Market Challenges

• Regulatory Concerns: Stringent regulations and approval variations create barriers.
• Generic Competition: Many generic formulations reduce pricing power.
• Adverse Effects Management: Potential neurotoxicity concerns require ongoing safety monitoring.

---

Competitive Landscape

Key Players	Market Share (%)	Strategies
Septodont	30	Product innovation, regional expansion
Dentsply Sirona	25	Acquisition, broad portfolio
Teva Pharmaceuticals	15	Cost leadership, manufacturing scale
Others	30	Niche players, generics

Numerous generic manufacturers also participate, intensifying price competition.

---

Regulatory and Patent Dynamics

Aspect	Details
Patent Status	Composition of matter patents typically expire around 2023–2025
Regulatory Approvals	FDA (USA), EMA (EU), and regional authorities approve various formulations
Innovation Pathways	Development of controlled-release formulations and combination products

Patent expirations open opportunities for generics but also diminish exclusivity. Regulatory pathways favor incremental innovations that improve safety or administration.

---

Financial Trajectory Projections

Year	Revenue Estimate (USD million)	Key Assumptions
2023	480	Continued market growth, rising adoption
2025	620	Introduction of innovative delivery systems
2030	900+	Greater penetration in emerging markets, new formulations

Forecast Model Components

• Market Penetration Rates: Increasing penetration in Asia-Pacific, Latin America.
• Pricing Trends: Slight downward pressure with increased generic competition, balanced by innovation premiums.
• Cost Structure: Manufacturing costs declining with scale, although regulatory compliance remains a factor.
• R&D Expenditure: Focus on new formulations, safety enhancements, and alternative delivery routes.

---

Market Entry and Investment Considerations

Factors	Insights
Regulatory Strategy	Early engagement with regional authorities essential for approval pathways
Product Differentiation	Focus on formulations with improved safety profiles and ease of injection
Manufacturing	Scalability and cost reduction through strategic partnerships
Market Expansion	Prioritize emerging markets where access barriers are lower
Patent Landscape	Monitor patent expiration timelines for potential generic entry

Long-term profitability hinges on innovation, regulatory compliance, and strategic regional expansion.

---

Comparison with Similar Local Anesthetics

Compound	Onset of Action	Duration	Peak Safety Concern	Patent Status	Market Penetration
Lidocaine	1-3 min	1-2 hours	Neurotoxicity	Expired	Widely used, mature
Mepivacaine	2-5 min	2-3 hours	Cardiovascular effects	Expired	Competitive
Articaine	1-2 min	1-2 hours	Neurotoxicity (monitoring required)	Patent expiry approaching	Growing, especially in dental

Articaine’s rapid onset and increased potency make it a preferred choice in specific dental applications, setting it apart from other local anesthetics.

---

Deep Dive: Regulatory Policies Impacting Investment

Region	Policy Overview	Impact on Market
United States	FDA approval via NDA; recent safety guidelines for neurotoxicity	Increased scrutiny; potential delays
European Union	EMA approval, flexible for formulations	Favorable for novel formulations
Emerging Markets	Varying standards; fast-track approvals in some countries	Opportunities for early movers

Aligning product development with evolving policies is critical for market entry and sustained sales.

---

FAQs

1. What factors are driving the growth of articaine hydrochloride in emerging markets?
   Rising dental healthcare awareness, expanding infrastructure, and lower treatment costs contribute significantly to market expansion in regions like Asia-Pacific and Latin America.

2. How does patent expiration influence the competitive landscape?
   Patent expiry around 2023–2025 opens opportunities for generic manufacturers, increasing competition and potentially reducing prices but also challenging brand dominance.

3. What are the main safety concerns associated with articaine hydrochloride?
   Neurotoxicity risks, especially when administered improperly, necessitate adherence to dosing guidelines and monitoring.

4. Are there ongoing innovations aimed at enhancing articaine formulations?
   Yes, developments include controlled-release systems, combination drugs, and needleless delivery methods, aiming to improve safety, efficacy, and patient comfort.

5. What regulatory hurdles could affect new market entries with articaine products?
   Variability in approval standards, safety data requirements, and regional patent laws pose challenges; early regulatory engagement is crucial.

---

Key Takeaways

• The global articaine hydrochloride market is projected to grow at approximately 11.4% CAGR through 2028, driven mainly by expanding dental procedures and emerging market penetration.
• Patent expirations around 2023–2025 will increase competition from generics, influencing pricing and market share dynamics.
• Innovation in formulations, safety profiles, and delivery methods are vital for maintaining competitive advantages.
• Regulatory landscapes vary, requiring strategic planning to navigate approval processes and compliance standards.
• Investment opportunities are concentrated in emerging markets, where access to dental health services is on the rise, and regulatory pathways are more flexible.

---

References

[1] Grand View Research, "Local Anesthetics Market Size, Share & Trends Analysis Report," 2023.